📊 BAX Key Takeaways
Is Baxter International Inc. (BAX) a Good Investment?
Baxter is experiencing severe profitability deterioration with negative operating and net margins despite revenue growth, indicating fundamental operational challenges rather than cyclical weakness. The company is burning shareholder value with negative ROE (-15.6%) and ROA (-4.8%), while maintaining elevated debt levels (1.54x D/E) that limit financial flexibility to address underlying issues.
Baxter shows modest top-line growth and remains free-cash-flow positive, but that growth is not translating into healthy profitability. Negative operating income, a sizable net loss, weak interest coverage, and elevated leverage point to strained earnings quality and limited financial flexibility until margins recover meaningfully.
Why Buy Baxter International Inc. Stock? BAX Key Strengths
- Positive revenue growth of 5.7% YoY demonstrates continued market demand
- Healthy liquidity position with 2.31x current ratio and $2.0B cash providing operational flexibility
- Positive operating cash flow of $845M and free cash flow of $332M showing some cash generation despite net losses
- Revenue grew 5.7% year over year, indicating underlying demand remains intact
- Liquidity is solid with a 2.31x current ratio and $1.97B in cash
- Operating cash flow and free cash flow remain positive, supporting ongoing operations and investment
BAX Stock Risks: Baxter International Inc. Investment Risks
- Significant operating losses (-$308M) and net losses (-$957M) indicating core business profitability crisis
- Deteriorating earnings per share (-47.2% YoY decline) suggests accelerating value destruction
- High leverage (1.54x D/E, $9.4B long-term debt) with negative interest coverage (-1.1x) creates vulnerability if operational performance doesn't improve
- Negative returns on equity and assets signal poor capital allocation and operational inefficiency
- Operating and net margins are negative, showing the business is not currently converting sales into profits
- High leverage with $9.44B of long-term debt and 1.54x debt-to-equity increases balance-sheet risk
- Negative interest coverage indicates earnings are insufficient to comfortably support debt servicing
Key Metrics to Watch
- Operating margin trend and path to profitability in next 2-3 quarters
- Gross margin sustainability and whether 30.1% can be maintained
- Debt reduction progress and interest coverage ratio recovery to positive territory
- Operating margin recovery and sustained improvement in net income
- Free cash flow expansion alongside reduction in long-term debt or stronger interest coverage
Baxter International Inc. (BAX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.0% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.31x current ratio provides a solid financial cushion.
BAX Profit Margin, ROE & Profitability Analysis
BAX vs Healthcare Sector: How Baxter International Inc. Compares
How Baxter International Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Baxter International Inc. Stock Overvalued? BAX Valuation Analysis 2026
Based on fundamental analysis, Baxter International Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Baxter International Inc. Balance Sheet: BAX Debt, Cash & Liquidity
BAX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Baxter International Inc.'s revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $5.23 reflects profitable operations.
BAX Revenue Growth, EPS Growth & YoY Performance
BAX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7B | -$46.0M | $-0.09 |
| Q2 2025 | $2.7B | $91.0M | $0.18 |
| Q1 2025 | $2.5B | $37.0M | $0.07 |
| Q3 2024 | $2.6B | -$137.0M | $-0.27 |
| Q2 2024 | $3.7B | -$97.0M | $-0.19 |
| Q1 2024 | $3.5B | $37.0M | $0.07 |
| Q3 2023 | $3.6B | $2.4B | $4.76 |
| Q2 2023 | $3.6B | -$97.0M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Baxter International Inc. Dividends, Buybacks & Capital Allocation
BAX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Baxter International Inc. (CIK: 0000010456)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BAX
What is the AI rating for BAX?
Baxter International Inc. (BAX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BAX's key strengths?
Claude: Positive revenue growth of 5.7% YoY demonstrates continued market demand. Healthy liquidity position with 2.31x current ratio and $2.0B cash providing operational flexibility. ChatGPT: Revenue grew 5.7% year over year, indicating underlying demand remains intact. Liquidity is solid with a 2.31x current ratio and $1.97B in cash.
What are the risks of investing in BAX?
Claude: Significant operating losses (-$308M) and net losses (-$957M) indicating core business profitability crisis. Deteriorating earnings per share (-47.2% YoY decline) suggests accelerating value destruction. ChatGPT: Operating and net margins are negative, showing the business is not currently converting sales into profits. High leverage with $9.44B of long-term debt and 1.54x debt-to-equity increases balance-sheet risk.
What is BAX's revenue and growth?
Baxter International Inc. reported revenue of $11.2B.
Does BAX pay dividends?
Baxter International Inc. pays dividends, with $348.0M distributed to shareholders in the trailing twelve months.
Where can I find BAX SEC filings?
Official SEC filings for Baxter International Inc. (CIK: 0000010456) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BAX's EPS?
Baxter International Inc. has a diluted EPS of $-1.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BAX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Baxter International Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BAX stock overvalued or undervalued?
Valuation metrics for BAX: ROE of -15.6% (sector avg: 15%), net margin of -8.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BAX stock in 2026?
Our dual AI analysis gives Baxter International Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BAX's free cash flow?
Baxter International Inc.'s operating cash flow is $845.0M, with capital expenditures of $513.0M. FCF margin is 3.0%.
How does BAX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.5% (avg: 12%), ROE -15.6% (avg: 15%), current ratio 2.31 (avg: 2).
Is Baxter International Inc. carrying too much debt?
BAX has a debt-to-equity ratio of 1.54x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.31 suggests adequate short-term liquidity.